ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AMGN Amgen Inc

305.84
-0.66 (-0.22%)
May 25 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,425,865
Bid Price 303.38
Ask Price 327.45
News -
Day High 307.50

Low
211.73

52 Week Range

High
329.72

Day Low 303.90
Company Name Stock Ticker Symbol Market Type
Amgen Inc AMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.66 -0.22% 305.84 00:00:03
Open Price Low Price High Price Close Price Prev Close
306.42 303.90 307.50 305.84 306.50
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
35,768 2,425,865 $ 306.17 $ 742,722,066 - 211.73 - 329.72
Last Trade Time Type Quantity Stock Price Currency
19:52:22 27 $ 305.03 USD

Amgen (AMGN) Options Flow Summary

Overall Flow

Bullish

Net Premium

472k

Calls / Puts

320.00%

Buys / Sells

110.00%

OTM / ITM

90.91%

Sweeps Ratio

0.05%

Amgen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
163.91B 535.92M - 28.19B 6.72B 12.53 24.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Amgen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AMGN Message Board. Create One! See More Posts on AMGN Message Board See More Message Board Posts

Historical AMGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week315.01316.67303.90311.032,011,943-9.17-2.91%
1 Month265.72322.54265.72302.002,868,65340.1215.10%
3 Months276.50322.54260.75283.772,664,53829.3410.61%
6 Months265.12329.72260.75288.042,739,10740.7215.36%
1 Year225.64329.72211.73269.272,658,40480.2035.54%
3 Years250.66329.72198.64248.552,717,42655.1822.01%
5 Years172.62329.72165.06238.512,694,620133.2277.18%

Amgen Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Your Recent History

Delayed Upgrade Clock